Safety, tolerability and effectiveness of generic HAART in HIV-Infected children in South India

Journal of Tropical Pediatrics

Volumn 55, Issue 3, 2009, Pages 155-159

  Kumarasamy, N ^a   Venkatesh, Kartik K ^b,c   Devaleenol, Bella ^a   Poongulali, S ^a   Moothi, S N ^d   Solomon, Suniti ^a  

^a VHS Medical Centre India   (India)

^b MIRIAM HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

^d Asha Kirana Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; GENERIC DRUG; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

AIDS RELATED COMPLEX; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LIPOATROPHY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRURITUS; THRUSH; VERTICAL TRANSMISSION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INDIA; INFANT; MALE; TREATMENT OUTCOME;

EID: 67149125836     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmn080     Document Type: Article

References (18)

1. UNAIDS. UNAIDS/WHO AIDS epidemic update, 2007. http://www.unaids.org/ epidemic-update/ (9 May 2008, date last accessed).
2. NACO. Policy Framework for Children with AIDS. http://www.nacoonline.org/ Quick_Links/Publication/Treatment_Care_Support/ Operational_Technical_guidelines_and_policies/ Policy_Framework-for-Children_with_AIDS/ (16 June 2008, date last accessed).
3. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. J Am Med Assoc 2006;296:292-300.
4. WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: Towards universal access, 2006. http://www.who.int/hiv/pub/guidelines/art/en/ (4 July 2008, date last accessed).
5. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis 2005;41:100-7.
6. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'lvoire. AIDS 2004;18:1905-13.
7. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: Evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007;120:e1134-40.
8. Song R, Jelagat J, Dzombo D, et al. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya. Pediatrics 2007;120:e856-61.
9. Kumarasamy N, Solomon S, Flanigan TP, et al. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003;36:79-85.
10. Kumarasamy N, Solomon S, Chaguturu SK, et al. The changing natural history of HIV disease: Before and after the introduction of generic antiretroviral therapy in southern India. Clin Infect Dis 2005;41:1525-8.
11. Madhivanan P, Mothi SN, Kumarasamy N, et al. Clinical manifestations of HIV infected children. Indian J Pediatr 2003;70:615-20.
12. Centers for Disease Control and Prevention. 1994 Revised Classification System for Human Immunodeficiency Virus Infection in Children Less than 13 Years of Age 1994 http://www.cdc.gov/mmwr/preview/mmwrhtml/ 00032890.htm (2 July 2008, date last accessed).
13. WHO. WHO Child Growth Standards: Methods and Development. http://www.who.int/childgrowth/standards/technical_report/en/index.html (1 July 2008, date last accessed).
14. Rajasekaran S, Jeyaseelan L, Ravichandran N, et al. Efficacy of antiretroviral therapy program in children in India: Prognostic factors and survival analysis. J Trop Pediatr 2008;in press.
15. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. J Am Med Assoc 2007;298:1888-99.
16. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006;52:244-8.
17. Shah I. Age related clinical manifestations of HIV infection in Indian children. J Trop Pediatr 2005;51:300-3.
18. Natu S, Daga SR. Antiretroviral therapy in children: Indian experience. Indian Pediatr 2007;44:339-43.